Am J Surg Pathol 2013 Oct;37(10):1469-89
*Department of Pathology and Molecular Medicine, McMaster University, Hamilton, ON, Canada †Department of Pathology and Molecular Medicine, Wellington School of Medicine, University of Otago, Wellington, New Zealand ‡Department of Pathology, Indiana University School of Medicine, Indianapolis, IN Departments of ∥Pathology, Urology and Oncology §§Pathology and Oncology, Johns Hopkins Medical Institutions, Baltimore, MD ††Memorial Sloan Kettering Cancer Centre, NY ‡‡Department of Pathology, in New York University Medical Centre, New York, NY §Department of Oncology and Pathology, Karolinska University Hospital Solna, Stockholm, Sweden ¶Department of Pathology, University Hospital Plzen, Plzen, Czech Republic #Institute of Surgical Pathology, University of Zurich, Switzerland **Section of Pathological Anatomy, Polytechnic University of Medicine, United Hospitals, Ancona, Italy.
The classification working group of the International Society of Urological Pathology consensus conference on renal neoplasia was in charge of making recommendations regarding additions and changes to the current World Health Organization Classification of Renal Tumors (2004). Members of the group performed an exhaustive literature review, assessed the results of the preconference survey and participated in the consensus conference discussion and polling activities. On the basis of the above inputs, there was consensus that 5 entities should be recognized as new distinct epithelial tumors within the classification system: tubulocystic renal cell carcinoma (RCC), acquired cystic disease-associated RCC, clear cell (tubulo) papillary RCC, the MiT family translocation RCCs (in particular t(6;11) RCC), and hereditary leiomyomatosis RCC syndrome-associated RCC. Read More